Gland Pharma Limited (BOM:543245)
India · Delayed Price · Currency is INR | Market Cap | 381.08B +62.2% |
| Revenue (ttm) | 64.31B +14.5% |
| Net Income | 10.27B +47.1% |
| EPS | 62.28 +46.9% |
| Shares Out | n/a |
| PE Ratio | 37.09 |
| Forward PE | 30.73 |
| Dividend | 20.00 (0.87%) |
| Ex-Dividend Date | Aug 11, 2026 |
| Volume | 66,248 |
| Open | 2,309.80 |
| Previous Close | 2,306.75 |
| Day's Range | 2,308.50 - 2,352.10 |
| 52-Week Range | 1,515.00 - 2,391.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,151.46 (-7.0%) |
| Earnings Date | May 15, 2026 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla... [Read more]
Financial Performance
In fiscal year 2026, Gland Pharma's revenue was 64.31 billion, an increase of 14.50% compared to the previous year's 56.17 billion. Earnings were 10.27 billion, an increase of 47.07%.
Financial StatementsNews
Top gainers today: gland pharma at ₹2,156.60 up 15.43%, coforge at ₹1,348.10 up 5.15%, persistent systems at ₹4,944.10 up 5.15%
In today's trading session, the Indian stock market displayed a modest upward trend, with the Sensex rising by 0.10% to 75,315.04 and the Nifty 50 inching up by 0.03% to…
Top gainers in morning trade: gland pharma at ₹2,127 up 13.85%, shipping corporation of India at ₹348.50 up 5.16%, carborundum universal at ₹1,139 up 3.32%
In the morning session, the Indian stock market displayed mixed sentiments as the SENSEX dipped to 74,789.97, marking a 0.60% decline, while the NIFTY 50 fell by 0.62% to 23,496.40.…
Why Gland Pharma shares are up over 12% today? Explained
Shares of Gland Pharma surged more than 12% in early trade on Monday after the company reported a strong set of Q4FY26 earnings, driven by robust growth in revenue, profitability,…
Gland Pharma Transcript: Q4 25/26
Q4 FY 2026 saw record revenue and profitability, led by CDMO growth, new launches, and Cenexi turnaround. FY 2027 guidance is 12%-13% revenue growth (constant currency), with further upside possible from GLP-1 contracts as partner approvals materialize.
Gland Pharma Quarterly report: Q4 2026
Gland Pharma has published its Q4 2026 quarterly earnings report on May 15, 2026.
Gland Pharma Slides: Q4 2026
Gland Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Gland Pharma reports audited financial results for year ending March 2026
Gland Pharma has announced its audited financial results for the quarter and financial year ending 31 March 2026. The results, which include both standalone and consolidated figures, have been reviewe...
Gland Pharma reports 97% growth in Q4 FY26 profit after tax
Gland Pharma, an injectable-focused pharmaceutical company, has announced its financial results for the fourth quarter and year ending 31 March 2026, showcasing significant growth in revenue and profi...
Gland Pharma Q4 Results: Net profit jumps 96% YoY to Rs 366.68 crore, revenue up 22%
Gland Pharma reported a strong performance for the quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis. The pharmaceutical company posted consolidated reve...
Top Q4 results today, May 15: Tata Steel, NHPC, Power Grid, Cochin Shipyard, Gland Pharma among key companies to announce earnings
Several listed companies are scheduled to announce their financial results for the quarter and financial year ended March 2026 on Friday, May 15, 2026. Major earnings to watch include announcements…
What To Expect From Gland Pharma Ltd (NSE:GLAND) Q4 2026 Earnings
What To Expect From Gland Pharma Ltd (NSE:GLAND) Q4 2026 Earnings
Gland Pharma to consider stock options grant under ESOP 2025 scheme
Gland Pharma has announced that its ESOP Compensation Committee will convene on Friday, May 15, 2026, to discuss and potentially approve the grant of stock options under the Gland Pharma…
Gland Pharma reappoints Naina Lal Kidwai as independent director with special remuneration terms
Gland Pharma has announced the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The decision, which was initially proposed in a postal ballot notice dated April 9, 2026,…
Pharma sector stocks today, April 7: Shukra Pharma up 5%, Max Healthcare falls 2.44%, Gland Pharma down 1.68%
Pharmaceutical sector stocks traded mostly lower in early deals on April 7, 2026. The S&P BSE Healthcare Index stood at 41,286.7, down 0.6%. The index has declined 5.6% over the…
Pharma sector stocks today, March 30: Suven Life surge 7.88%, Wockhardt up 3.27%, Gland Pharma falls 2.36%
As of approximately 9:33 AM IST on March 30, 2026 (BSE prices) and 9:34 AM IST (NSE prices), most pharma sector stocks on the BSE and NSE were trading in…
Pharma sector stocks surge today, March 18: Alembic jumps 2.87%, Panacea Biotec up 2.84%, Gland Pharma rises 2.69%
The pharmaceutical sector stocks in India showed positive movement on March 18, 2026, during early trading hours, with many scrips recording gains on both BSE and NSE. The S&P BSE…
Gland Pharma gets USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution
Gland Pharma Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OT...
Pharma sector stocks down today, Feb 24: AstraZeneca Pharma falls 1.72%, Alembic Pharma down 1.38%, Gland Pharma drops 1.24%
The Indian pharmaceutical sector experienced a modest decline on February 24, 2026, amid broader market weakness. The S&P BSE HEALTHCARE...
Gland Pharma gets USFDA nod for Zoledronic Acid Injection for US market
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Gland Pharma shares rally sharply over 8% as Q3 revenue rises 22.5% YoY to Rs Rs 1,695 crore, net profit up 27.7%
Gland Pharma shares surged over 8% in early morning trade after the company reported a strong set of consolidated results...
Top stocks for trade today, Jan 29: Wipro, Mahindra, Garden Reach, Gland Pharma, Larsen & Toubro and more
Indian equities are likely to see stock-specific action today, January 29, as several companies announced quarterly results, partnerships, and order...
Gland Pharma Transcript: Q3 25/26
Q3 FY 2026 delivered 22% revenue growth and 25% higher adjusted EBITDA, driven by strong U.S. and European performance, Cenexi turnaround, and new product launches. Five-year CapEx of INR 2,000 crore targets capacity expansion, with 12%-13% growth expected for FY 2027 and a 15% five-year CAGR.
Gland Pharma Quarterly report: Q3 2026
Gland Pharma has published its Q3 2026 quarterly earnings report on January 28, 2026.
Gland Pharma Slides: Q3 2026
Gland Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 28, 2026.
Gland Pharma Q3 Results: Revenue jumps 22.5% YoY to Rs 1,695 crore, net profit up 27.5% YoY
Gland Pharma has announced its Q3 financial results, reporting strong year-on-year growth across key operational and profitability metrics, supported by...